FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017044611> ?p ?o ?g. }

• W2017044611 endingPage "2517" @default.
• W2017044611 startingPage "2507" @default.
• W2017044611 abstract "We conducted a randomized, controlled, multicenter, phase II study to evaluate the immunogenicity and safety of an investigational intradermal (ID) trivalent influenza vaccine (TIV) and a high-dose (HD) intramuscular (IM) TIV in older adults (≥65 years of age). Older adult subjects were immunized with ID vaccine containing either 15μg hemagglutinin (HA)/strain (n=636) or 21μg HA/strain (n=634), with HD IM vaccine containing 60μg HA/strain (n=320), or with standard-dose (SD) IM vaccine (Fluzone(®); 15μg HA/strain; n=319). For comparison, younger adults (18-49 years of age) were immunized with SD IM vaccine. In older adults, post-vaccination geometric mean titers induced by the ID vaccines were superior to those induced by the SD IM vaccine for the A/H1N1 and A/H3N2 strains and non-inferior for the B strain. Seroconversion rates induced by the ID vaccines were superior to those induced by the SD IM vaccine in older adults for the A/H1N1 and B strains and non-inferior for the A/H3N2 strain. Results did not differ significantly for the two ID vaccine dosages. Post-vaccination geometric mean titers, seroconversion rates, and most seroprotection rates were significantly higher in HD vaccine recipients than in older adult recipients of the SD IM or ID vaccines and, for most measures, were comparable to those of younger adult SD IM vaccine recipients. Injection-site reactions, but not systemic reactions or unsolicited adverse events, were more common with the ID vaccines than with the IM vaccines. No treatment-related serious adverse events were reported. This study demonstrated that: (1) the ID and HD vaccines were well-tolerated and more immunogenic than the SD IM vaccine in older adults; (2) the HD vaccine was more immunogenic than the ID vaccines in older adults; and (3) the HD vaccine in older adults and the SD IM vaccine in younger adults elicited comparable antibody responses (ClinicalTrials.gov identifier no.: NCT00551031)." @default.
• W2017044611 created "2016-06-24" @default.
• W2017044611 creator A5016661637 @default.
• W2017044611 creator A5028253446 @default.
• W2017044611 creator A5028844100 @default.
• W2017044611 creator A5031728953 @default.
• W2017044611 creator A5034516058 @default.
• W2017044611 creator A5050021298 @default.
• W2017044611 creator A5060681308 @default.
• W2017044611 creator A5085048296 @default.
• W2017044611 date "2014-05-01" @default.
• W2017044611 modified "2023-10-06" @default.
• W2017044611 title "Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial" @default.
• W2017044611 cites W1631728354 @default.
• W2017044611 cites W1964541451 @default.
• W2017044611 cites W1965540493 @default.
• W2017044611 cites W1966882334 @default.
• W2017044611 cites W1969709506 @default.
• W2017044611 cites W1969841948 @default.
• W2017044611 cites W1971863415 @default.
• W2017044611 cites W1975608837 @default.
• W2017044611 cites W1977526385 @default.
• W2017044611 cites W1980062145 @default.
• W2017044611 cites W2000620937 @default.
• W2017044611 cites W2000988011 @default.
• W2017044611 cites W2018506527 @default.
• W2017044611 cites W2029823634 @default.
• W2017044611 cites W2040851514 @default.
• W2017044611 cites W2055173921 @default.
• W2017044611 cites W2058144955 @default.
• W2017044611 cites W2062666761 @default.
• W2017044611 cites W2073367505 @default.
• W2017044611 cites W2082803365 @default.
• W2017044611 cites W2083253013 @default.
• W2017044611 cites W2095069717 @default.
• W2017044611 cites W2100802425 @default.
• W2017044611 cites W2116058039 @default.
• W2017044611 cites W2118490555 @default.
• W2017044611 cites W2118873626 @default.
• W2017044611 cites W2119384523 @default.
• W2017044611 cites W2139841187 @default.
• W2017044611 cites W2150442039 @default.
• W2017044611 cites W2152368843 @default.
• W2017044611 cites W2157916202 @default.
• W2017044611 cites W2159458195 @default.
• W2017044611 cites W2164949714 @default.
• W2017044611 cites W2168407206 @default.
• W2017044611 doi "https://doi.org/10.1016/j.vaccine.2013.09.074" @default.
• W2017044611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24120672" @default.
• W2017044611 hasPublicationYear "2014" @default.
• W2017044611 type Work @default.
• W2017044611 sameAs 2017044611 @default.
• W2017044611 citedByCount "66" @default.
• W2017044611 countsByYear W20170446112013 @default.
• W2017044611 countsByYear W20170446112014 @default.
• W2017044611 countsByYear W20170446112015 @default.
• W2017044611 countsByYear W20170446112016 @default.
• W2017044611 countsByYear W20170446112017 @default.
• W2017044611 countsByYear W20170446112018 @default.
• W2017044611 countsByYear W20170446112019 @default.
• W2017044611 countsByYear W20170446112020 @default.
• W2017044611 countsByYear W20170446112021 @default.
• W2017044611 countsByYear W20170446112022 @default.
• W2017044611 crossrefType "journal-article" @default.
• W2017044611 hasAuthorship W2017044611A5016661637 @default.
• W2017044611 hasAuthorship W2017044611A5028253446 @default.
• W2017044611 hasAuthorship W2017044611A5028844100 @default.
• W2017044611 hasAuthorship W2017044611A5031728953 @default.
• W2017044611 hasAuthorship W2017044611A5034516058 @default.
• W2017044611 hasAuthorship W2017044611A5050021298 @default.
• W2017044611 hasAuthorship W2017044611A5060681308 @default.
• W2017044611 hasAuthorship W2017044611A5085048296 @default.
• W2017044611 hasBestOaLocation W20170446111 @default.
• W2017044611 hasConcept C126322002 @default.
• W2017044611 hasConcept C159047783 @default.
• W2017044611 hasConcept C159654299 @default.
• W2017044611 hasConcept C168563851 @default.
• W2017044611 hasConcept C197934379 @default.
• W2017044611 hasConcept C203014093 @default.
• W2017044611 hasConcept C22070199 @default.
• W2017044611 hasConcept C2777451964 @default.
• W2017044611 hasConcept C2780689484 @default.
• W2017044611 hasConcept C2780868878 @default.
• W2017044611 hasConcept C32611913 @default.
• W2017044611 hasConcept C71924100 @default.
• W2017044611 hasConceptScore W2017044611C126322002 @default.
• W2017044611 hasConceptScore W2017044611C159047783 @default.
• W2017044611 hasConceptScore W2017044611C159654299 @default.
• W2017044611 hasConceptScore W2017044611C168563851 @default.
• W2017044611 hasConceptScore W2017044611C197934379 @default.
• W2017044611 hasConceptScore W2017044611C203014093 @default.
• W2017044611 hasConceptScore W2017044611C22070199 @default.
• W2017044611 hasConceptScore W2017044611C2777451964 @default.
• W2017044611 hasConceptScore W2017044611C2780689484 @default.
• W2017044611 hasConceptScore W2017044611C2780868878 @default.
• W2017044611 hasConceptScore W2017044611C32611913 @default.
• W2017044611 hasConceptScore W2017044611C71924100 @default.
• W2017044611 hasFunder F4320333684 @default.

• next